-6.2% · 90d
$19.94
+0.07 (+0.35%)
After-Hours $19.94(+0.00)
News
(1)April 2026
DNLI files proxy statement detailing 2026 board election and governance votes
DNLIDenali Therapeutics Inc.
# 📄 What This Document Is 📜 This is a **Proxy Statement (DEF 14A)**, which is essentially a mandatory informational packet sent to stockholders before a major annual meeting. It isn't an earnings report, but rather a formal guide detailing exactly what decisions the company wants you to vote on.
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%